Heart failure with preserved ejection fraction
Conditions
Brief summary
Time to hospitalization due to heart failure exacerbation or cardiovascular death.
Detailed description
Time to hospitalization for cardiovascular reasons; Time to hospitalization for any reason; Time to cardiovascular death; Time to death from any cause; EQ-5D score; KCCQ-12 score, NYHA Class, CCS Class; Level of biomarkers related to endothelial function; Inflammation biomarkers levels; Level of biomarkers associated with heart failure; Endothelial function parameters (FMD); Microcirculation Function Parameters (LSCI); Left ventricular systolic function parameters (ejection fraction
Interventions
DRUGTrimeductan MR
DRUG35 mg
DRUGtabletki o zmodyfikowanym uwalnianiu
DRUGPlacebo for Trimeductan MR 35/Placebo dla Trimeductan MR 35
Sponsors
Medical University Of Gdansk
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to hospitalization due to heart failure exacerbation or cardiovascular death. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to hospitalization for cardiovascular reasons; Time to hospitalization for any reason; Time to cardiovascular death; Time to death from any cause; EQ-5D score; KCCQ-12 score, NYHA Class, CCS Class; Level of biomarkers related to endothelial function; Inflammation biomarkers levels; Level of biomarkers associated with heart failure; Endothelial function parameters (FMD); Microcirculation Function Parameters (LSCI); Left ventricular systolic function parameters (ejection fraction | — |
Countries
Poland
Outcome results
None listed